Substitute for PTO-1390 (Rev. 07-2005) "Transmittal Letter to the United States Designated/Elected Office(DO/EO/US)Concerning a Submission Under 35 U.S.C. 371" Approved for use through 3/31/2007. OMB 0651-0021

U. S. PAT	ATTORNEY'S DOCKET NUMBER							
U.S.	21334YP							
TRANSMITTAL LETTER DESIGNATED/ELECTE	U.S. APPLICATION NO. (If known, see 37 CFR 1.5)							
CONCERNING A FILIN	10/572342							
INTERNATIONAL APPLICATION NO.		PRIORITY DATE CLAIMED						
PCT/US2004/030486	September 17, 2004	September 23, 2003						
TITLE OF INVENTION ISOQUINOLINE POTASSIUM CHANNEL INHIBITORS								
APPLICANT(S) FOR DO/EO/US								
B. Wesley Trotter, Kausik K. Nanda, Nathan R. Kett, Christopher J. Dinsmore, Gerald S. Ponticello, and David A. Claremon								
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:								
1. X This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.								
<ol> <li>This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.</li> </ol>								
3. This is an express request to begin national examination procedures [35 U.S.C. 371(f)]. The submission must								
	include items (5), (6), (9) and (21) indicated below.  4.  \implies \text{The US has been elected (PCT Article 31).}							
<del></del>								
b. has been communicated by the International Bureau.								
c. X is not required, as the application was filed in the United States Receiving Office (RO/US).								
6. An English language translation of the International Application as filed [35 U.S.C. 371(c)(2)].  a. is attached hereto								
b. has been previously submitted under 35 U.S.C. 154(d)(4).								
7. Amendments to the claims of the International Application under PCT Article 19 [35 U.S.C. 371(c)(3)].  a. are attached hereto (required only if not communicated by the International Bureau).								
b. have been communicated by the International Bureau.								
c.  have not been made; however, the time limit for making such amendments has NOT expired.								
d. have not been made a	d. have not been made and will not be made.							
8. An English language translat	An English language translation of the amendments to the claims under PCT Article 19 [35 U.S.C. 371(c)(3)].							
9. An oath or declaration of the	An oath or declaration of the inventor(s) [35 U.S.C. 371(c)(4)].							
10. An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 [35 U.S.C. 371(c)(5)].  Items 11 to 20 below concern other document(s) or information included:								
	tatement under 37 CFR 1.97 and 1.98.							
	. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31							
13. A preliminary amendment.	is included.  A preliminary amendment.							
14. An Application Data Sheet u								
15. A substitute specification.	5. A substitute specification.							
16. A power of attorney and/or of	16. A power of attorney and/or change of address letter.							
7. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825.								
8. A second copy of the published International Application under 35 U.S.C.154(d)(4).								
19. A second copy of the English	19. A second copy of the English language translation of the international application under 35 U.S.C.154(d)(4).							
20. Other items or information:								

Substitute for PTO-1390 (Rev. 07-2005) "Transmittal Letter to the United States Designated/Elected Office(DO/EO/US)Concerning a Submission Under 35 U.S.C. 371"

Androved for use through 3/31/2007. OMB 0651-0021

0.5. AT LICATION NO. (II known, see 37 CFR 1.5)		INTERNATIONAL APPLICATION NO.			ATTORNEY'S DOCKET NUMBER				
201512342 PC		PCT/US	PCT/US2004/030486			21334YP			
The following fees are submitted:					<del>_</del>	CALCULATIONS	PTO USE ONLY		
21. X Basic national fee\$300				\$300	\$300.00				
22. X Examinat	ion fee (	37 CFR 1.492	2(c))						
					preliminary examination report f PCT Article 33(1)-(4)		¢o		
1								\$200.00	
23. X Search fee	(37 CFI	R 1.492(b))		····	<del></del> -			Ψ200.00	
					ninary examination report preparation				
					e 33(1)-(4)ional application to the USPTC				
International Searchin	g Autho	rity						\$100.00	
International Search Report prepared by an ISA other than the US and provided to the Office or previously communicated to the US by the IB						\$400			
All other situations									
					TOTAL OF 2	1, 22	and 23=	\$600.00	
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of									
paper or fraction						LIONA			
Total Sheets	Extra	Sheets			additional 50 or fraction p to a whole number)		RATE		
115 - 100 =	15	/50	0.3	_	1	Х	\$250.00	\$250.00	
Surcharge of \$130.0	l O for fur	nishing the oa	th or decla	ration la	ater than 30 months from the ea	rliest	claimed	4250.00	
priority date [37 CF]									
CLAIMS		NUMBER	FILED		NUMBER EXTRA		RATE		
Total Claims			23	- 20 =	3	X	\$50.00	\$150.00	
Independent Claims			1	- 3 =	0	X	\$200.00	\$0.00	
MULTIPLE DEPENI	DENT C	LAIM(S) (if a	ipplicable)			+	\$360.00		
TOTAL OF ABOVE CALCULATIONS (SUBTOTAL) =						\$1,000.00			
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest									
claimed priority date (37 CFR 1.492(f)]. + TOTAL NATIONAL FEE =						\$1,000.00			
Fee for recording the enclosed assignment [37 CFR 1.21(h)]. The assignment must be									
accompanied by an a	арргоргіа	ite cover shee	et (37 CFR	3.28, 3.3	31).\$40.00 per property.		+		
TOTAL FEES ENCLOSED =						=	\$1,000.00		
								Amount to be	
						refunded:			
								Amount to be charged:	
a. A check in the amount of \$ to cover the above fees is enclosed.									
b. Please charge my Deposit Account No. 13-2755 in the amount of \$1,000.00 to cover the above fees.									
A duplicate copy of this sheet is enclosed.									
c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to the Deposit Account No. 13-2755. A duplicate copy of this sheet is enclosed.									
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive [37 CFR 1.137(a) or									
(b)] must be filed and granted to restore the International Application to pending status.									
SEND ALL CORRESPONDENCE TO:									
Customer No. 000210									
<u>i</u>									
MERCK & CO., INC. Patent Department, RY60-30									
P.O. Box 2000 SIGNATURE									
126 East Lincolr Rahway, New Je									
1 Timirray, 140 W Je	iscy U	303-0970					S. Parr	<del></del>	<del></del>
DATE: March 17, 2006 NAME									
PHONE # (732) 594-4958									
REGISTRATION NUMBER									

7 HAR 2006

## Page 1A of TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371

21334YP

International Filing Date:	<u>September 17, 2004</u>				
<b>Priority Date:</b>	<u>September 23, 2003</u>				
Title:	ISOQUINOLINE POTASSIUM CHANNEL INHIBITORS				
Inventors:	B. Wesley Trotter, Kausik K. Nanda, Nathan R. Kett, Christopher J. Dinsmore, Gerald S. Ponticello and David A.				
	Claremon				

PCT/US2004/030486

**EXPRESS MAIL CERTIFICATE** 

DATE OF DEPOSIT March 17, 2006

EXPRESS MAIL NO. EL989589642US

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE" ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO COMMISSIONER FOR PATENTS P.O. BOX 1450, ALEXANDRIA, VIRGINIA 22313-1450.

MAILED BY

**Attorney Docket No.:** 

**International Appln No.:**